Heron Therapeutics Inc. (NASDAQ:HRTX)’s share price rose 6.9% during trading on Tuesday . The company traded as high as $18.92 and last traded at $18.06, with a volume of 1,265,450 shares traded. The stock had previously closed at $16.90.

HRTX has been the subject of a number of analyst reports. Brean Capital reaffirmed a “buy” rating and issued a $55.00 price target on shares of Heron Therapeutics in a report on Friday, May 6th. Jefferies Group reaffirmed a “buy” rating and issued a $46.00 price target on shares of Heron Therapeutics in a report on Wednesday, July 27th. Leerink Swann reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Monday, June 27th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $41.00 price target on shares of Heron Therapeutics in a report on Friday, June 24th. Finally, Noble Financial reiterated a “buy” rating and issued a $51.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, April 20th. One equities research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $50.30.

The firm’s 50 day moving average price is $17.51 and its 200-day moving average price is $18.90.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.92) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.92). Equities analysts forecast that Heron Therapeutics Inc. will post ($3.65) earnings per share for the current year.

Several large investors have modified their holdings of HRTX. California State Teachers Retirement System increased its stake in shares of Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the last quarter. GAM Holding AG increased its stake in shares of Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the last quarter. Russell Frank Co increased its stake in shares of Heron Therapeutics by 46.9% in the fourth quarter. Russell Frank Co now owns 48,830 shares of the biotechnology company’s stock worth $1,369,000 after buying an additional 15,585 shares during the last quarter. Swiss National Bank acquired a new stake in shares of Heron Therapeutics during the fourth quarter worth about $1,100,000. Finally, California Public Employees Retirement System increased its stake in shares of Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares during the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.